Table 1.
Intratumor heterogeneous (ITH) cases according to total high-risk neuroblastomas (HR-NB) studied, their genomic profile (MYCN non-amplified, non-MNA; MYCN amplified, MNA; or with heterogeneous amplification of MYCN, hetMNA) and the combination of samples analysed in each case.
| ITH Cases/Total HR-NB Cases | ITH Cases/Total Genomic Profile Cases | ITH Cases/Combination of Samples Analysed | |
|---|---|---|---|
| 22/58 HR-NB (37.9%) | 14/32 non-MNA (44% ITH) | 2/13 (15.4%) | T1 + T2 |
| 11/17 (64.7%) | T + LB | ||
| - | 7/8 T1 + LB | ||
| 4/9 T1 + T2 + LB | |||
| 1/2 (50.0%) | LBp + LBm | ||
| 8/20 MNA (40% ITH) | 3/6 (50.0%) | T1 + T2 | |
| 5/14 (35.7%) | T + LB | ||
| - | 5/13 T1 + LB | ||
| - | 0/1 T1 + T2 + LB | ||
| 0/6 hetMNA (0% ITH) | 0/5 (0.0%) | T1 + T2 | |
| 0/4 T1 + T2 | |||
| 0/1 T1 + T2 + T3 | |||
| 0/1 (0.0%) | T + LB | ||
| 0/1 T1 + T2 + T3+ LB | |||
| - | - | Total | 93 T |
| - | - | 36 LB | |
| - | - | 129 samples | |
T: solid tumor (1, 2, 3); LB: liquid biopsy, LBp: liquid biopsy from peripheral blood, LBm: liquid biopsy from medullary aspirate.